Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
Kai M, Hikita H, Kazuki M, Tahata Y, Shinkai K, Doi A, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Kaneko A, Iio S, Nawa T, Kakita N, Morishita N, Hiramatsu N, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Oze T, Kodama T, Tatsumi T, Takehara T. Kai M, et al. Among authors: sakakibara m. PLoS One. 2024 Jan 2;19(1):e0294590. doi: 10.1371/journal.pone.0294590. eCollection 2024. PLoS One. 2024. PMID: 38165900 Free PMC article.
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.
Shirai K, Hikita H, Sakamori R, Doi A, Tahata Y, Sakane S, Kamada Y, Murai K, Nishio A, Yamada R, Kodama T, Nozaki Y, Kakita N, Ishida H, Nakanishi F, Morishita N, Imanaka K, Sakakibara M, Tatsumi T, Miyoshi E, Takehara T. Shirai K, et al. Among authors: sakakibara m. PLoS One. 2022 Dec 21;17(12):e0279416. doi: 10.1371/journal.pone.0279416. eCollection 2022. PLoS One. 2022. PMID: 36542633 Free PMC article.
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Ohkawa K, Oshita M, Miyazaki M, Yakushijin T, Nozaki Y, Matsumoto K, Tanaka S, Kaneko A, Iio S, Nawa T, Yamada Y, Morishita N, Usui T, Hiramatsu N, Doi Y, Sakakibara M, Imanaka K, Yoshida Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Maesaka K, et al. Among authors: sakakibara m. PLoS One. 2023 Feb 7;18(2):e0281459. doi: 10.1371/journal.pone.0281459. eCollection 2023. PLoS One. 2023. PMID: 36749777 Free PMC article.
Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells.
Kakita N, Kanto T, Itose I, Kuroda S, Inoue M, Matsubara T, Higashitani K, Miyazaki M, Sakakibara M, Hiramatsu N, Takehara T, Kasahara A, Hayashi N. Kakita N, et al. Among authors: sakakibara m. Int J Cancer. 2012 Dec 1;131(11):2573-83. doi: 10.1002/ijc.27535. Epub 2012 Mar 29. Int J Cancer. 2012. PMID: 22419479 Free article.
Development of a thrombus in the superior mesenteric artery associated with sequential therapy with tyrosine kinase inhibitors for hepatocellular carcinoma.
Nawa T, Katayama K, Kiyota R, Imai T, Abe Y, Hasegawa N, Takada R, Fukutake N, Ikezawa K, Sakakibara M, Fujita M, Ohkawa K. Nawa T, et al. Among authors: sakakibara m. Clin J Gastroenterol. 2020 Apr;13(2):247-251. doi: 10.1007/s12328-019-01021-6. Epub 2019 Jul 17. Clin J Gastroenterol. 2020. PMID: 31317371
Prognostic Factors for Patients With a Large Number of Hepatocellular Carcinoma Nodules.
Abe Y, Ohkawa K, Sakakibara M, Nawa T, Fukutake N, Ikezawa K, Takada R, Kusakabe A, Imai T, Nakanishi K, Tabuchi T, Hikita H, Sakamori R, Tatsumi T, Takehara T, Katayama K. Abe Y, et al. Among authors: sakakibara m. J Clin Med Res. 2020 Jan;12(1):26-35. doi: 10.14740/jocmr4032. Epub 2020 Jan 6. J Clin Med Res. 2020. PMID: 32010419 Free PMC article.
Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment.
Maesaka K, Sakamori R, Yamada R, Tahata Y, Oshita M, Hagiwara H, Sakakibara M, Tamura S, Hiramatsu N, Inada M, Iio S, Ito T, Yakushijin T, Doi Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Maesaka K, et al. Among authors: sakakibara m. Hepatol Res. 2021 May;51(5):517-527. doi: 10.1111/hepr.13623. Epub 2021 Mar 9. Hepatol Res. 2021. PMID: 33507588
Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration.
Shinkai K, Sakamori R, Yamada R, Tahata Y, Nozaki Y, Matsumoto K, Tawara S, Fukuda K, Yoshida Y, Tanaka S, Ito T, Doi Y, Iio S, Sakakibara M, Nakanishi F, Kodama T, Hikita H, Tatsumi T, Takehara T. Shinkai K, et al. Among authors: sakakibara m. J Gastroenterol Hepatol. 2022 Jun;37(6):1148-1155. doi: 10.1111/jgh.15853. Epub 2022 Apr 26. J Gastroenterol Hepatol. 2022. PMID: 35430734
Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.
Tahata Y, Sakamori R, Maesaka K, Doi A, Yamada R, Kodama T, Hikita H, Miyazaki M, Nozaki Y, Kaneko A, Oshita M, Tanaka S, Imanaka K, Hiramatsu N, Morishita N, Ohkawa K, Yakushijin T, Sakakibara M, Iio S, Doi Y, Tatsumi T, Takehara T. Tahata Y, et al. Among authors: sakakibara m. Hepatol Res. 2023 Apr;53(4):301-311. doi: 10.1111/hepr.13868. Epub 2022 Dec 22. Hepatol Res. 2023. PMID: 36507871
461 results